CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
4.280
-0.420 (-8.94%)
At close: Jun 22, 2026, 4:00 PM EDT
4.200
-0.080 (-1.87%)
After-hours: Jun 22, 2026, 4:16 PM EDT
CNS Pharmaceuticals Employees
CNS Pharmaceuticals had 8 employees as of December 31, 2025. The number of employees increased by 3 or 60.00% compared to the previous year.
Employees
8
Change (1Y)
3
Growth (1Y)
60.00%
Revenue / Employee
n/a
Profits / Employee
-$2,060,786
Market Cap
6.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 3 | 60.00% | 8 | 0 |
| Dec 31, 2024 | 5 | 0 | - | 4 | 1 |
| Dec 31, 2023 | 5 | 0 | - | 3 | 2 |
| Dec 31, 2022 | 5 | 0 | - | 3 | 2 |
| Dec 31, 2021 | 5 | 0 | - | 3 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 40 |
| Imunon | 20 |
| Purple Biotech | 10 |
| Immuron | 7 |
| Ernexa Therapeutics | 7 |
| Can-Fite BioPharma | 5 |
| Acurx Pharmaceuticals | 4 |
| Silo Pharma | 3 |
CNSP News
- 14 days ago - CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment - Accesswire
- 4 weeks ago - CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress - Accesswire
- 4 weeks ago - CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders - TheFly
- 4 weeks ago - CNS Pharmaceuticals Registration statement: Registration filing - Filings
- 5 weeks ago - CNS Pharmaceuticals reports Q1 EPS ($7.30) vs. ($18.93) last year - TheFly
- 5 weeks ago - CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months - TheFly
- 5 weeks ago - CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress - Accesswire
- 5 weeks ago - CNS Pharmaceuticals Quarterly report: Q1 2026 - Filings